Board summary
Key figures
134,022
Registered population
61.4% aged 18–64
17.2%
Aged 65+
ICB 19.0% · England 17.9%
11.4%
Ethnic minority (non-White)
3.9% Asian · England 9.6%
67.0%
In IMD quintile 1
ICB 31.9% · England 21.0%
~80,771
Core20 residents (est.)
Resident basis; registered basis ~93,683 · see page 3
22,594
Hypertension register
+2.40% in 3 yrs · England +5.60%
1,814
SMI register
21.6% of Liverpool (LAD)'s
4,922
COPD register
Reviews +4.93% in 3 yrs
Forecast to 2030
24,352
Hypertension patients, 2030
+1,758 on today
67.7%
QRISK ≥20% on statins, 2030
+0.06pp over 3 yrs
4.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Age-five MMR2 and pre-school boosters lag.
Age-5 MMR2 is 74.0% (England 82.8%), 13.4 pp below MMR1 (87.4%), and 4-in-1 is 71.6%, which may reflect recall gaps to check locally.
Heart failure reviews and statin trends trail.
From 2023 to 2025, heart failure reviews changed -1.9% (England +8.7%) to 74.4% and QRISK >=20% lipid therapy +0.1% (England +6.2%), warranting recall audits.
Hypertension blood pressure control matches England.
Hypertension treatment to target is 70.0% (England 70.3%, ICB 69.1%), rising +6.2% from 2023 to 2025 (England +3.6%) and +7.1% in under-80s.
Population, age and ethnicity
Children make up 21.4% of the list alongside above-average inclusion health registers
North Liverpool PCN registers 134,022 patients across its member practices. Children aged 0-17 comprise 21.4% (28,650 patients), above Liverpool (19.8%), the ICB (19.2%), and England (19.6%). Patients aged 65+ account for 17.2% (23,099), exceeding Liverpool (15.6%) but below the ICB (19.0%) and England (17.9%). Projected list growth is 2.0% to 2030, trailing Liverpool (3.0%), the ICB (2.3%), and England (2.3%), though projection methodology remains unverified. Residential Census data shows 88.5% White ethnicity (Liverpool 84.0%, ICB 93.0%, England 81.1%) and an 11.4% ethnic minority share; Census residency does not establish registered-patient ethnicity.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Liverpool (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Liverpool LA) | 3,035 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 82.9% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 53.0% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Liverpool LA) | 1,652 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Liverpool LA) | 27.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Deprivation is severe across 19 practices, with 67.0% of patients in Core20 areas
The PCN has an average IMD decile of 2.5 and 67.0% of registered patients live in Core20 areas, compared with 54.9% in Liverpool, 31.9% in the ICB and 21.0% in England. In 19 of 21 practices, Core20 share exceeds England. Concentration reaches 100.0% at practices including Westminster Medical Centre, while Ellergreen Medical Centre carries the largest volume with 11,427 estimated Core20 patients. Weighted practice share is 69.9% versus the PCN rate of 67.0%, a discrepancy requiring base reconciliation before resource targeting.
PLUS groups and inclusion health
PLUS groups and inclusion health
1,814
SMI register
1.32% recorded prevalence
987
Learning disability register
0.72% recorded prevalence
43
Care homes, 1,349 beds
In the PCN catchment
10.3%
Provide unpaid care
Liverpool (LAD), Census 2021
The PCN records 1,814 patients on the severe mental illness register (1.3% vs Liverpool 1.4%, ICB 1.1%, England 1.0%) and 987 with learning disabilities (0.7% vs Liverpool 0.6%, ICB 0.6%, England 0.6%). Catchment capacity includes 43 care homes with 1,349 beds, though beds do not establish patient registration. Crude register prevalence does not establish unmet need, though recorded registers and local care home capacity define cohorts for structured annual reviews.
Severe mental illness: physical health checks
For patients on severe mental illness registers, 80.1% received a blood pressure check (England 83.4%), 80.6% had BMI recorded (England 82.1%), and 79.2% had alcohol status recorded (England 81.8%). Lower completion could reflect outreach barriers, testable by practice audits.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
22,594
Hypertension register
+2.40%
Register growth, 3 yrs
Liverpool (LAD) +2.01% · England +5.60%
+4.48pp
BP control, under 80
≤140/90 · +1.16pp aged 80+
+1,758
More patients by 2030
Forecast 24,352 (17.23%)
Hypertension case-finding and control
Hypertension recorded prevalence is 16.4% (22,594 patients), above Liverpool (14.0%) and England (15.2%) but below NHS Cheshire and Merseyside Integrated Care Board (16.8%). From 2023 to 2025, register growth was +2.4%, trailing England (+5.6%). Recent blood pressure checks reached 88.5% (England 90.0%), with 70.0% treated to target (England 70.3%). For patients aged 80 and over, 81.6% achieved blood pressure <= 150/90 mmHg (England 81.2%), with 2023 to 2025 growth of +1.4% (England +2.2%). Trailing three-year growth and recent checks could reflect review backlogs, which clinical recall audits would test.
Lipids and statins
Patients with QRISK ≥ 20% receiving lipid lowering therapy reached 67.6% (England 63.6%), though 2023 to 2025 growth was +0.1% (England +6.2%). In diabetes, statin treatment for patients aged 40 and over without cardiovascular disease was 71.8% (England 73.2%). Flat lipid therapy growth could reflect initiation gaps to test via recall audits.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 279,086 | £2.00 | £1.71 | £1.86 | £558,172 |
| Cardiovascular (all), 2025 | 392,365 | £3.74 | £4.37 | £3.33 | £1,467,445 |
For lipid-regulating drugs in 2026, the PCN prescribed 279,086 items at £2.00 per item (Liverpool £1.82, England £1.86, ICB £1.71), spending £39,072 more than at England's unit cost. Unit cost reflects drug choice rather than efficiency. Reviewing lipid-regulating prescribing choices could align PCN expenditure closer to benchmark unit costs.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+2.79%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.03%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 3.6% (4,922 patients; England 1.9%), with 77.4% reviewed in the last 12 months (England 76.4%). On the 8,555-patient asthma register (prevalence 6.6%, England 6.6%), 64.8% had an annual review (England 65.7%), leaving about 3,000 unreviewed. For asthma patients aged 6-19, second-hand smoke recording reached 73.0% (England 78.8%), while asthma prescribing reached 2,200 items per 1,000 aged 5-19 (England 1,488 rate). Lower review rates alongside high paediatric prescribing could reflect follow-up bottlenecks, which record audits would test.
Cancer register and children's immunisation
Cancer register prevalence is 3.6% (4,899 patients; England 3.8%). In Q1 2025/26, 6-in-1 coverage at 12 months was 88.0% (England 91.0%). Across 366 children aged 5, 4-in-1 booster coverage was 71.6% (England 80.9%, below the 95.0% target by 23.4 pp). Age-5 MMR dose 2 was 74.0% (England 82.8%), trailing MMR dose 1 (87.4%) by 13.4 pp. Dose drop-off could reflect pre-school recall timing, testable by child health list audits.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In NHS Cheshire and Merseyside ICB in 2022 (wider system data, not PCN level), 55.5% of staged cancers (7,482 of 13,490 staged cases) were diagnosed at stage 1 or 2, rising +2.6 pp from 52.8% in 2013 and remaining 19.5 pp below the 75.0% National ambition by 2028. This represents an ICB gap of about 2,640 extra early diagnoses annually, while 72.8% had a known stage. Locally, North Liverpool PCN records 4,899 cancer patients (3.6% prevalence; England 3.8%). Cervical screening coverage for women aged 25 to 49 is 64.7% (England 66.8%), including 42.6% at Fairfield Medical Centre, 54.0% at Stanley Medical Centre, and 56.5% at Anfield Group Practice.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Liverpool University Hospitals NHS Foundation Trust, 75.5% of patients met the 28-day faster diagnosis standard, 0.5 pp above the 75.0% standard. However, 62-day referral-to-treatment performance reached 73.3% (11.7 pp below the 85.0% standard), and the 31-day combined standard reached 90.5% (5.5 pp below the 96.0% standard). Across NHS Cheshire and Merseyside Integrated Care Board, faster diagnosis reached 77.2% (2.2 pp above standard) and 62-day treatment was 76.2% (8.8 pp below standard). These trust and ICB measures describe wider system performance and do not establish PCN referrals or PCN-level waits.
| Pathways within standard (%) | Liverpool | Mersey and West Lancashire | Wirral | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 75.47 | 72.39 | 74.71 | 77.25 | 79.32 |
| 31-day treatment (96%) | 90.51 | 95.46 | 92.53 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 73.26 | 77.96 | 77.65 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Liverpool | Mersey and West Lancashire | Wirral | England |
|---|---|---|---|---|
| MRI | 6.42 | 14.04 | 1.54 | 21.40 |
| CT | 0.71 | 13.08 | 1.55 | 9.92 |
| Echocardiography | 12.55 | 34.88 | 5.07 | 28.48 |
| Colonoscopy | 33.14 | 18.04 | 32.81 | 30.83 |
| Gastroscopy | 44.99 | 18.17 | 17.73 | 29.02 |
| All 15 DM01 tests | 11.50 | 21.17 | 5.02 | 23.14 |
| Community services activity | Liverpool residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 127,380 | 541,280 |
| Referrals | 15,675 | 97,150 |
| Patients with a contact | 24,970 | 146,240 |
Community services (residents of Liverpool), Jun 2026 (provisional). In provisional community services data for June 2026, adults aged 65 and over accounted for 65.4% of contacts among Liverpool borough residents (83,300 of 127,380 contacts). These borough-level contacts were not captured at PCN level, describing wider system activity rather than PCN primary care delivery.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Moss Way | 115 | 91.1 | 94.0% | 80.6% | 95.0% |
| Poulter Road | 102 | 37.4 | 89.7% | 68.6% | 91.2% |
| Derby Lane | 98 | 69.7 | 84.6% | 72.7% | 89.3% |
| Gillmoss | 113 | 90.8 | 72.6% | 76.6% | 88.9% |
| Fir Tree | 122 | 0.0 | 57.0% | 82.9% | 85.0% |
| Bousfield - Dr | 82 | 100.0 | 57.7% | 65.5% | 84.4% |
| Walton | 117 | 88.3 | 58.5% | 79.2% | 82.7% |
| Jubilee | 134 | 51.4 | 45.2% | 62.6% | 79.1% |
| Stoneycroft | 101 | 48.8 | 71.1% | 69.2% | 77.6% |
| Aintree Park | 106 | 18.2 | 48.1% | 74.1% | 76.3% |
| Langbank | 103 | 94.9 | 48.6% | 62.0% | 76.2% |
| Stanley | 83 | 100.0 | 54.1% | 67.7% | 72.8% |
| Fairfield | 99 | 100.0 | 26.9% | 78.5% | 70.5% |
| Long Lane | 120 | 78.9 | 38.2% | 73.2% | 70.4% |
| Westminster | 96 | 100.0 | 37.1% | 61.8% | 69.2% |
| Anfield | 96 | 97.4 | 42.9% | 58.1% | 68.5% |
| Kirkdale | 97 | 100.0 | 51.1% | 54.4% | 67.8% |
| Ellergreen | 91 | 88.2 | 31.4% | 50.2% | 66.4% |
| Grey Road | 91 | 83.3 | 34.1% | 69.7% | 64.8% |
| Bousfield - | 97 | 100.0 | 52.1% | 80.1% | 64.1% |
| Westmoreland GP | 115 | 35.7 | 26.7% | 69.7% | 63.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fourteen of 25 three-year trends trail England, led by falling heart failure reviews
Fourteen of 25 tracked three-year trends trail England. Heart failure reviews fell 1.9% (England +8.7%), while recorded prevalence changed by -3.7% for learning disability (England +5.4%), -3.1% for COPD (England +2.6%), and -1.3% for stroke (England +2.3%). Smoking cessation offers fell 0.9 pp (England +0.1 pp). Conversely, relative gains exceeded England in breast screening (+13.7% vs +8.4%), non-frail diabetes HbA1c control (+9.4% vs +4.4%), and under-80 blood pressure control (+7.1% vs +3.2%). Slower register growth alongside falling reviews could reflect follow-up bottlenecks, to test via recall audits.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Learning disability register
QRISK statin treatment
COPD register
Stroke register
Breast screening (53-70)
Diabetes HbA1c control
BP control, under 80
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Liverpool (LAD) | Asset | PCN | Liverpool (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 43 (1,349 beds) | n/a | Schools (catchment) | 218 | n/a |
| Children's centres | 14 | 26 | Places of worship | 98 | 240 |
| Libraries | 7 | 17 | Homelessness support (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 46 | 91 | Primary academies | 7 | 20 |
| Special schools | 4 | 8 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Asthma structured annual review recall
On the 8,555-patient asthma register, 64.8% had a 12-month review (England 65.7%, Liverpool 64.3%), leaving 3,016 (about 3,000) unreviewed; age 6-19 second-hand smoke recording is 73.0% (England 78.8%). For discussion: practices could run a single-template asthma recall and offer after-school or holiday review slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Age-five MMR2 and booster catch-up
In Q1 2025/26 across 366 children aged 5, MMR2 is 74.0% (England 82.8%, below the 95.0% target by 21 pp, and 13.4 pp below MMR1 at 87.4%); 4-in-1 is 71.6% (below 95.0% by 23.4 pp). Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Coordinated SMI annual physical checks
Across 1,814 patients on the SMI register, 12-month blood pressure checks reached 80.1% (England 83.4%, ICB 81.3%), BMI recording 80.6% (England 82.1%), and alcohol recording 79.2% (England 81.8%). For discussion: practices could combine SMI check components into single appointments, audit partial-check coding, and assign outreach leads. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Paediatric access and capacity review (p2) | Aged 0-17 | Medium Term Planning Framework 2026 · Neighbourhood health framework | PCN |
| Core20 outreach and capacity allocation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall audit (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension case finding audit (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Asthma structured annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Age-five MMR2 and booster catch-up (p12) | MMR dose 2 coverage at age 5 · MMR dose 1 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · Coordinated SMI annual physical checks (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
